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SUMMARY 
The synthesis of the 4-[I 1 Clmethylamino derivative of N-{N-[4- 
(4-Aminophenyl)butyryl]-L-prolyl}pyrrolidine (SUAM-1221), i s 
described as a potential marker for prolyl endopeptidase for in 
vivo positron emission tomography studies. Direct methylation of 
the 4-amino derivative of SUAM-1221 (1) with methyl iodide 
provided a mixture of the 4-monomethyl (2) and 4-dimethylamino 
(2) derivatives which were separated by chromatography. 
Methylation of 1 with [ I  1 Clmethyl iodide provided the 4- 
[I  1 Clmethylamino derivative of SUAM-1221, ([I 1C l l ) ,  in 18 - 30% 
decay corrected radiochemical yield after HPLC purification, with 
a specific activity >1700 Ci/mmol and a 40 minute synthesis 
time from end of bombardment. 
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INTRODUCTION 
Prolyl endopeptidase ([E.C.3.4.21.26]; PEP) is a serine protease widely 
distributed among various tissues throughout the body including the central 
nervous system (1 ). Many neuropeptides including neurotensin, Substance P, 
angiotensin I I ,  bradykinin and vasopressin have been shown to be substrates 
of PEP in vitro lending strong support for an important role for this enzyme 
in the biological regulation of these neuropeptides (2,3). Recent studies by 
Terwel (4) and lshiura (5) also suggest a role for PEP in the etiology of 
Alzheimers disease. The development of suitable in vivo markers for PEP 
that cross the blood-brain-barrier could therefore be useful for 
understanding the physiological role of this enzyme in the brain in health 
and disease using positron emission tomography (PET). 
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Atack and coworkers (6) recently reported on a series of high affinity 
( IC50 of mouse brain enzyme inhibition of 2 t o  5 nM), competitive, 
nonpeptide PEP inhibitors based on the prototypical PEP inhibitor SUAM- 
1221 (Figure 1 ). These compounds also displayed in vivo inhibition of brain 
PEP indicating that they cross the blood-brain-barrier. Furthermore, their 
studies revealed that the 4 position of the aromatic ring could tolerate both 
small as well as large substituents with no significant decrease in inhibitor 
activity. 
R = H ;  SUAM-1221 
R = NH2 ; 1 
R = NHCH3 ; - 2 
R=N(CH3)2; 3 
Figure 1. Structure of SUAM-1221 derivatives 
SUAM-1221 and its derivatives all contain a proline residue in the L 
configuration, which presumably is critical t o  biological activity as 
observed in the Z-Pro-prolinal class of PEP inhibitors (7). We report here the 
synthesis of  a carbon-1 1 labeled derivative of  SUAM-1221, ([11C]2), 
substituted a t  the 4 position of the aromatic ring (Figure 1 )  as a potential 
PET radiotracer for PEP. 
RESULTS AND DISCUSSION 
The chemical structure of  SUAM-1221 does not allow for a 
straightforward, convenient synthesis of the corresponding carbon-1 1 
labeled analog. In view of the reported high in vitro PEP inhibitory activity 
of 1 (IC50 for mouse brain PEP = 3.1 nM) and its ability t o  inhibit mouse and 
rat  brain PEP i n  v i vo  (6), the synthesis of  the corresponding 
[I 1 Clmethylamino analog [I 1 C]Z was therefore pursued. 
Synthesis of the monomethylamino and dimethylamino analogs 2 and 3, 
respectively, was achieved in a combined yield of 70% by direct N- 
methylation of 1 with 0.75 equivalents of CH31 in refluxing DMF : EtOH as 
shown in Figure 2. Integration of the methyl singlets in the 1H NMR of the 
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crude product mixture revealed a 1:l  mixture of these two products which 
were separated by flash chromatography. 
Direct N-[I 1Clmethylation of 1 with [ I  1 CICH31 provided [ I  l C ] 2  in high 
radiochemical yields (1 8 - 30%; decay corrected based on [ I  1 CICO2) and in 
high specific activity (>1700 Ci/mmol; end of  synthesis). No radioactive 
products corresponding t o  [ I  1 C]Q were detected by either TLC or HPLC 
analysis of the crude reaction mixture. 
CH31 
DMFEtOH ; llO°C * 
R = H (2) and R = CH3 (3) 
Figure 2. Synthesis of SUAM-1221 derivatives 
Compounds 1 and 2 showed baseline resolution (retention times for 1 
and 2 were 6.7 and 12.1 min respectively) under analytical reverse-;base 
HPLC conditions. There was concern however that on a preparative scale, 
HPLC purified [ I  1 C ] 2  could contain traces of the first eluting precursor 1 
due t o  tailing since the latter is present in large molar excess. Purification 
was therefore done using normal-phase conditions as described which 
provided [I 1 C]Z in high radiochemical and chemical purity (>95%). The 
identity of  [I 1 C ] 2  was confirmed by TLC and HPLC analysis. In a typical 
production run an average of 67 mCi (N = 5), of formulated [ I  1 C ] 2  were 
obtained from an estimated average of 1.26 Ci of [ I  1 CJC02 in a 40 minute 
synthesis time. 
In summary, we have described a convenient and efficient synthesis of 
a carbon-1 1 labeled derivative of the prolyl endopeptidase inhibitor SUAM- 
7221 as a potential marker for PEP in the central nervous system. Evaluation 
of this radiotracer in small animals is currently underway and will be 
reported shortly. 
MATERIALS AND METHODS 
Infrared spectra were recorded on a Perkin-Elmer Model 727B 
spectrometer. 1H-NMR spectra were obtained on a Bruker WM 360  MHz 
spectrometer with tetramethylsilane (TMS) as internal standard. Mass 
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spectra were obtained on a Finnigan 4021 GCMS/DS (low resolution) or a 
UG70-250-S (high resolution) instrument. 
(1) was 
synthesized according t o  the published method (6). All chemical reagents 
were of  reagent grade and purchased from Aldrich Chemical Company, 
Milwaukee, Wl. 
Flash chromatography was performed by the method of Still et aL(8). 
Thin-layer chromatography was performed on either Analtech silica gel GF 
or Whatman reversed phase (C-18) glass-backed plates (1 0 cm, 250 pm). TLC 
was performed by co-spotting the labeled compound with the authentic 
unlabeled compound prior t o  development. Radiochemical purity was 
monitored using the following TLC systems: 1) Silica; CHC13: CH3OH: NH40H 
( 9 8 2 1 ) ;  Rf of 1, 2 and3 were 0.18, 0.31 and 0.41 respectively; 
2) C-18; 95 % EtOH: 0.1 M NH40Ac (1 : 1 ); Rf of 1,2 and 3 were 0.67, 0.44 and 
0.28 respectively. TLC plates were scanned for radioactivity using a 
Berthold Model LB 2832 TLC-linear analyzer equipped with a Model LB 500 
data acquisition system. 
HPLC analysis was performed on a Phenomenex Ultremex 5 ODS column 
(Sp, 250 x 4.6 mm) eluted with 95% EtOH: 0.1 M NH40Ac (40:60) at a flow 
rate of 1 mL per minute. UV absorbance was monitored at 254 nm. The 
retention times of 1, 2, and 3. were 6.7, 12.1 and 29.8 min respectively 
under these assay conditions. HPLC purification of the radiolabeled product 
was performed on a Phenomenex Partisil 10  silica gel column (lop, 250 x 
9.4 mm) eluted with CH2CI2: isopropanol: diethylamine (975:25:1) at a flow 
rate of 7 mL per minute. The retention time of [I 1 C ] L  was 5.8 min; 
retention times for 1 and 3 were 10.5 and 3.7 mins respectively under these 
assay conditions. UV absorbance (254 nm) and radioactivity were monitored 
by an in-line UV absorbance and gamma-detector. 
Specific activity determinations were made by collection of the 
radioactive peak corresponding t o  [I 1 C ] 2 ,  measurement of the U.V. 
absorbance peak area of carrier 2 by an automated integrator and 
comparison with the area of a standard sample of 2. 
N - I N - [ 4 - ( 4 -Am i no p h e n y I ) b u t  y r y I ] - L- p r o I y I } p y r r o  I i d i n e 
Production of [I  ICICHQI 
[I 1 C]CO2 was produced with a biomedical cyclotron (CS-30 
accelerator; Cyclotron Corporation) by the 1 4N(p,a)l  1 C reaction using 
nitrogen in an all aluminum target. [I 1C]COz was converted to  [11C]CH30H by 
LiAIH4 reduction, and treated with aqueous HI at reflux (9,lO) t o  generate 
[I 1CICH31. 
The initial activity of the [I 1C]CO2 produced at bombardment was 
estimated from a previously determined standard curve of 1 1 C activity 
produced versus irradiation times in the same target. Estimates of initial 
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target activity from this standard curve were used t o  determine overall 
radiochemical yields. 
N-{ N-[4-(4-{ KMethylamino } phenyl)butyryl]-L-prolyl) pyrrolidine 
(2) and N-{N-[4-(4-{ N,KDimethylamino}phenyl)butyryl]-L-prolyl]- 
pyrrolidine (3) 
A solution of 1 (0.248 g, 0.75 mmol) in dry DMF: absolute EtOH (1 :l; 10 
mL) was stirred and treated dropwise a t  23 OC with a solution of CH31 
(0.082 g, 36 pL, 0.58 mmol) in absolute EtOH (1.5 mL). The reaction mixture 
was heated a t  reflux at 1 1  0 OC for 4 hours and the EtOH removed by 
rotoevaporation. Residual DMF was then removed at 60 OC by means of a 
vacuum pump. The crude product was partitioned between 1 N NaOH (50 mL) 
and EtOAc (50 mL) and the organic layer removed. The aqueous layer was 
extracted once with EtOAc (50 mL) and the combined organic layers washed 
with H20 (100 mL) and dried (Na2S04). Removal of volatiles gave a light 
brown oil which was flash chromatographed with CHC13: CH30H: NH40H 
(98:2:1) to  afford 73 mg (37%) of 2 and 68 mg (33%) of 3 as pale yellow 
oils. 
2: IR (KBr) 3350, 1633 cm-1; 1 H NMR (CDC13): 6 7.01 (d, J = 8.4 Hz, 2H), 
6.55 (d, J = 8.4 Hz, 2H), 4.63 (dd, l H ) ,  3.83 (9, lH), 3.65 - 3.53 (m, 2H), 3.45 - 
3.33 (m, 3H), 2.81 (s, 3H), 2.56 (t, J = 7.3 Hz, 2H), 2.32 - 2.19 (m, 3H), 2.10 - 
1.80 (m, 9H); MS (El, 70 eV), rn/z(relative intensity): 343 (M+, 13.4), 176 
(76), 134 (15.6), 133 (48.3), 120 (50.6), 112 (loo), 70 (79.8), 55 (15.4); 
High resolution MS (El, 70 eV) calculated for C20H2gN302: 343.2260. 
Found: 343.2261. 
3: IR (KBr) 3450 (broad), 1625 cm-1; 1H NMR (CDC13): 6 7.07 (d, J = 8.7 Hz, 
2H), 6.69 (d, J = 8.7 Hz, 2H), 4.64 (dd, lH), 3.84 (4, lH), 3.66 - 3.53 (m, ZH), 
3.46 - 3.34 (m, 3H), 2.90 (s, 6H), 2.58 (t, J = 7.4 Hz, 2H), 2.33 - 2.19 (m, 3H), 
2.10 - 1.78 (m, 9H); MS (El, 70 eV), m/z (relative intensity): 357 (M+, 18.5), 
190 (77.6), 147 (loo), 134 (72.8), 112 (91.6), 70 (71.3), 55 (15.9); 
High resolution MS (El, 70 eV) calculated for C21 H31 N3O2: 357.241 6. Found : 
357.2426. 
N- { N - [ 4 - (4 - { N- [ 1 1 C] Met h y I a m i no } p h e n y I) b u t y ry I ] -L- pro I y I } 
pyrrolidine; ([I 1 CIZ) 
[I  1 CIMethyl iodide carried by a nitrogen stream was trapped in a reaction 
vial containing a solution of 1 (1.2 mg , 9 pmol) in DMF (0.1 5 mL) a t  -30 to  
-40 OC. The reaction mixture was heated at 95 OC for 5 min, then purged 
with nitrogen for 1 5 seconds t o  remove unreacted [ I  1 CICH31. The reaction 
mixture was then diluted with water (0.5 mL) and transferred by remote 
handling onto a short reversed phase column (300 mg C-18; PrepSep; Fisher 
Scientific) that had been prewashed with methanol (50 mL) followed by 
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water (1 00 mL). The extraction column was rinsed with water (1 .O mL) and 
dried by passing nitrogen through it a t  80 psi for 2 minutes. The crude 
[I 1 C ] 2  was then eluted off the C-18 guard column with the HPLC mobile 
phase (CHzC12: isopropanol: diethylamine [975:25:1]) onto a semi-preparative 
silica column for purification. The radioactive peak corresponding t o  [I 1C]2 
was collected in a sterile vial and the solvent removed using low heat 
(40 O C )  and a nitrogen flow. The residue was formulated in phosphate 
buffered saline (pH = 6.0) and filtered through a 0.2 pm alumina filter 
(Anotop) into a sterile 10  mL multidose vial. The decay corrected 
radiochemical yield ranged from 18 - 30% (N = 5); and the specific activity 
was determined to  be >1700 Ci/mmol a t  end of synthesis. 
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